Istradefylline – a first generation adenosine A_2A antagonist for the treatment of Parkinson’s disease

References

• Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of parkinson’s disease. Mov Disord. 2018;33:1248–1266.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72:S1–136.
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of parkinson’s disease. N Engl J Med. 2004;351:2498–2508.
   PubMed Web of Science ®Google Scholar
• Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015;30:80–89.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Latapi P, Bhowmick SS, Saranza G, et al. Non-dopaminergic treatments for motor control in parkinson’s disease: an update. CNS Drugs. 2020;34:1025-1044.
   PubMed Web of Science ®Google Scholar
• Hung AY, Schwarzschild MA. Treatment of parkinson’s disease: what’s in the non-dopaminergic pipeline? Neurotherapeutics. 2014;11:34–46.
   PubMed Web of Science ®Google Scholar
• Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in parkinson’s disease. Ann Neurol. 2004;55:761–765.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Neuropathological staging of brain pathology in sporadic parkinson’s disease: separating the wheat from the chaff. J Parkinsons Dis. 2017;7:S71–S85.
   PubMedGoogle Scholar
• Obeso JA, Marin C, Rodriguez-Oroz C, et al. The basal ganglia in parkinson’s disease: current concepts and unexplained observations. Ann Neurol. 2008;64(Suppl 2):S30–46.
   PubMedGoogle Scholar
• Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of parkinson’s disease: review of recent trials. Mov Disord. 2013;28:131–144.
   PubMed Web of Science ®Google Scholar
• Duty S, Jenner P. Animal models of parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011;164:1357–1391.
   PubMed Web of Science ®Google Scholar
• Compta Y, Tolosa E. Anticholinergic medications. In: Koller WC, Melamed E, editors. Handbook of Clinical Neurology. Vol. 84. Amsterdam, Netherlands. Elsevier; 2007. p. 121–125.
   Google Scholar
• Crispo JAG, Willis AW, Thibault DP, et al. Associations between anticholinergic burden and adverse health outcomes in Parkinson disease. PLoS One. 2016;11:e0150621.
   PubMed Web of Science ®Google Scholar
• Kong M, Ba M, Ren C, et al. An updated meta-analysis of amantadine for treating dyskinesia in parkinson’s disease. Oncotarget. 2017;8:57316–57326.
   PubMedGoogle Scholar
• Amantadine and other antiglutamate agents: management of Parkinson’s disease. Mov Disord. 2002;17(Suppl 4):S13–22.
   PubMedGoogle Scholar
• Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (ease lid study): a randomized clinical trial. JAMA Neurol. 2017;74:941–949.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Yamashita H, Zhang YX, et al. Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res Bull. 1996;41:363–367.
   PubMed Web of Science ®Google Scholar
• Mizoguchi K, Yokoo H, Yoshida M, et al. Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism. Brain Res. 1994;662:255–258.
   PubMed Web of Science ®Google Scholar
• Peeters M, Page G, Maloteaux JM, et al. Hypersensitivity of dopamine transmission in the rat striatum after treatment with the NMDA receptor antagonist amantadine. Brain Res. 2002;949:32–41.
   PubMed Web of Science ®Google Scholar
• Gianutsos G, Chute S, Dunn JP. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur J Pharmacol. 1985;110:357–361.
   PubMed Web of Science ®Google Scholar
• Elkurd MT, Bahroo LB, Pahwa R. The role of extended-release amantadine for the treatment of dyskinesia in parkinson’s disease patients. Neurodegener Dis Manage. 2018;8:73–80.
   PubMed Web of Science ®Google Scholar
• Bermejo PE, Anciones B. A review of the use of zonisamide in parkinson’s disease. Ther Adv Neurol Disord. 2009;2:313–317.
   PubMedGoogle Scholar
• Iwaki H, Tagawa M, Iwasaki K, et al. Comparison of zonisamide with non-levodopa, anti-parkinson’s disease drugs in the incidence of parkinson’s disease-relevant symptoms. J Neurol Sci. 2019;402:145–152.
   PubMed Web of Science ®Google Scholar
• Sonsalla PK, Wong LY, Winnik B, et al. The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010;221:329–334.
   PubMed Web of Science ®Google Scholar
• Yamamura S, Ohoyama K, Nagase H, et al. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology. 2009;57:322–331.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Takahashi S. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J Neural Transm. 1993;5:27–34.
   Web of Science ®Google Scholar
• Sahli ZT, Tarazi FI. Pimavanserin: novel pharmacotherapy for parkinson’s disease psychosis. Expert Opin Drug Discov. 2018;13:103–110.
   PubMed Web of Science ®Google Scholar
• Kianirad Y, Simuni T. Pimavanserin, a novel antipsychotic for management of parkinson’s disease psychosis. Expert Rev Clin Pharmacol. 2017;10:1161–1168.
   PubMed Web of Science ®Google Scholar
• Li Z, Yu Z, Zhang J, et al. Impact of rivastigmine on cognitive dysfunction and falling in parkinson’s disease patients. Eur Neurol. 2015;74:86–91.
   PubMed Web of Science ®Google Scholar
• Henderson EJ, Lord SR, Close JC, et al. The respond trial–rivastigmine to stabilise gait in parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with parkinson’s disease who have fallen. BMC Neurol. 2013;13:188.
   PubMed Web of Science ®Google Scholar
• Milardi D, Quartarone A, Bramanti A, et al. The cortico-basal ganglia-cerebellar network: past, present and future perspectives. Front Syst Neurosci. 2019;13:61.
   PubMed Web of Science ®Google Scholar
• Nutt JG, Bohnen NI. Non-dopaminergic therapies. J Parkinsons Dis. 2018;8:S73–S78.
   PubMedGoogle Scholar
• Haskó G, Pacher P, Vizi ES, et al. Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci. 2005;26:511–516.
   PubMed Web of Science ®Google Scholar
• Parkinson FE, Xiong W, Zamzow CR. Astrocytes and neurons: different roles in regulating adenosine levels. Neurological Res. 2005;27:153–160.
   PubMed Web of Science ®Google Scholar
• Klotz KN, Hessling J, Hegler J, et al. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg’s Arch Pharmacol. 1998;357:1–9.
   Google Scholar
• Fredholm BB, Abbracchio MP, Burnstock G, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev. 1994;46:143–156.
   PubMed Web of Science ®Google Scholar
• Jarvis MF, Williams M. Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. Eur J Pharmacol. 1989;168:243–246.
   PubMed Web of Science ®Google Scholar
• Rosin DL, Robeva A, Woodard RL, et al. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol. 1998;401:163–186.
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Hall H, Sedvall G, et al. Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse. 1997;27:322–335.
   PubMed Web of Science ®Google Scholar
• Ishiwata K, Mishina M, Kimura Y, et al. First visualization of adenosine A2A receptors in the human brain by positron emission tomography with [11C]TMSX. Synapse. 2005;55:133–136.
   PubMed Web of Science ®Google Scholar
• Ferré S, Fredholm BB, Morelli M, et al. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 1997;20:482–487.
   PubMed Web of Science ®Google Scholar
• Mori A, Shindou T. Modulation of Gabaergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology. 2003;61:S44–8.
   PubMedGoogle Scholar
• Jenner P, Mori A, Hauser R, et al. Adenosine, adenosine A2A antagonists, and parkinson’s disease. Parkinsonism Relat Disord. 2009;15:406–413.
   PubMed Web of Science ®Google Scholar
• Cui G, Jun SB, Jin X, et al. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature. 2013;494:238–242.
   PubMed Web of Science ®Google Scholar
• Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem. 1991;57:1062–1067.
   PubMed Web of Science ®Google Scholar
• Ena SL, De Backer JF, Schiffmann SN, et al. FACS array profiling identifies ecto-5ʹ nucleotidase as a striatopallidal neuron-specific gene involved in striatal-dependent learning. J Neurosci. 2013;33:8794–8809.
   PubMed Web of Science ®Google Scholar
• Augusto E, Matos M, Sévigny J, et al. Ecto-5ʹ-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions. J Neurosci. 2013;33:11390–11399.
   PubMed Web of Science ®Google Scholar
• Kuwana Y, Shiozaki S, Kanda T, et al. Antiparkinsonian activity of adenosine A2A antagonists in experimental models. Adv Neurol. 1999;80:121–123.
   PubMedGoogle Scholar
• Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000;162:321–327.
   PubMed Web of Science ®Google Scholar
• Hodgson RA, Bertorelli R, Varty GB, et al. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther. 2009;330:294–303.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10:221–229.
   PubMed Web of Science ®Google Scholar
• Factor SA, Wolski K, Togasaki DM, et al. Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson’s disease. Mov Disord. 2013;28:817–820.
   PubMed Web of Science ®Google Scholar
• Michel A, Downey P, Van Damme X, et al. Behavioural assessment of the A2A/NR2B combination in the unilateral 6-OHDA-lesioned rat model: a new method to examine the therapeutic potential of non-dopaminergic drugs. PLoS One. 2015;10:e0135949.
   PubMed Web of Science ®Google Scholar
• Michel A, Nicolas JM, Rose S, et al. Antiparkinsonian effects of the “Radiprodil and Tozadenant” combination in MPTP-treated marmosets. PLoS One. 2017;12:e0182887.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Olanow CW, Kieburtz KD, et al. Tozadenant (SYN115) in patients with parkinson’s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014;13:767–776.
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S, Borgohain R, Kellett M, et al. The adenosine A2A receptor antagonist BIIB014 is effective in improving ON-time in parkinson’s disease (PD) patients with motor fluctuations. Mov Disord. 2010;25(Suppl 2):S305.
   Google Scholar
• Pinna A, Pontis S, Borsini F, et al. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of parkinson’s disease. Synapse. 2007;61:606–614.
   PubMed Web of Science ®Google Scholar
• Pinna A. Adenosine A2A receptor antagonists in parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014;28:455–474.
   PubMed Web of Science ®Google Scholar
• Aoyama S, Kase H, Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci. 2000;20:5848–5852.
   PubMed Web of Science ®Google Scholar
• Ochi M, Shiozaki S, Kase H. Adenosine A2A receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of parkinson’s disease. Neuroscience. 2004;127:223–231.
   PubMed Web of Science ®Google Scholar
• Mori A. Chapter four - mode of action of adenosine A2a receptor antagonists as symptomatic treatment for parkinson’s disease. In: Mori A, editor. International Review of Neurobiology. Vol. 119. London, UK. Academic Press; 2014. p. 87–116.
   Google Scholar
• Mori A. How do adenosine A(2A) receptors regulate motor function? Parkinsonism Relat Disord. 2020;80(Suppl 1):S13–s20.
   PubMedGoogle Scholar
• Canals M, Marcellino D, Fanelli F, et al. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem. 2003;278:46741–46749.
   PubMed Web of Science ®Google Scholar
• Fuxe K, Ferre S, Canals M, et al. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J Mol Neurosci. 2005;26:209–220.
   PubMed Web of Science ®Google Scholar
• Chen JF, Moratalla R, Impagnatiello F, et al. The role of the D2 dopamine receptor (D2R) in A2A adenosine receptor (A2AR)-mediated behavioral and cellular responses as revealed by A2A and D2 receptor knockout mice. Proc Natl Acad Sci USA. 2001;98:1970–1975.
   PubMed Web of Science ®Google Scholar
• Ramlackhansingh AF, Bose SK, Ahmed I, et al. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology. 2011;76:1811–1816.
   PubMed Web of Science ®Google Scholar
• Mishina M, Ishiwata K, Naganawa M, et al. Adenosine A2A receptors measured with [C]TMSX PET in the striata of parkinson’s disease patients. PLoS One. 2011;6:e17338–e17338.
   PubMed Web of Science ®Google Scholar
• Hettinger BD, Lee A, Linden J, et al. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of gabaergic neurons in rat striatum. J Comp Neurol. 2001;431:331–346.
   PubMed Web of Science ®Google Scholar
• Corsi C, Melani A, Bianchi L, et al. Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. Neuroreport. 2000;11:2591–2595.
   PubMed Web of Science ®Google Scholar
• Corsi C, Melani A, Bianchi L, et al. Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. Neuroreport. 1999;10:687–691.
   PubMed Web of Science ®Google Scholar
• Preston Z, Lee K, Widdowson L, et al. Adenosine receptor expression and function in rat striatal cholinergic interneurons. Br J Pharmacol. 2000;130:886–890.
   PubMed Web of Science ®Google Scholar
• Richardson PJ, Dixon AK, Lee K, et al. Correlating physiology with gene expression in striatal cholinergic neurones. J Neurochem. 2000;74:839–846.
   PubMed Web of Science ®Google Scholar
• Tozzi A, de Iure A, Di Filippo M, et al. The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for parkinson’s disease. J Neurosci. 2011;31:1850–1862.
   PubMed Web of Science ®Google Scholar
• Schiffmann SN, Libert F, Vassart G, et al. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci Lett. 1991;130:177–181.
   PubMed Web of Science ®Google Scholar
• Fink JS, Weaver DR, Rivkees SA, et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res. 1992;14:186–195.
   PubMedGoogle Scholar
• Augood SJ, Emson PC. Adenosine A2A receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. Brain Res Mol Brain Res. 1994;22:204–210.
   PubMedGoogle Scholar
• Svenningsson P, Le Moine C, Aubert I, et al. Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J Comp Neurol. 1998;399:229–240.
   PubMed Web of Science ®Google Scholar
• Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in parkinson’s disease. Trends Neurosci. 2000;23:S8–19.
   PubMed Web of Science ®Google Scholar
• Schiffmann SN, Fisone G, Moresco R, et al. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol. 2007;83:277–292.
   PubMed Web of Science ®Google Scholar
• Calon F, Dridi M, Hornykiewicz O, et al. Increased adenosine A2A receptors in the brain of parkinson’s disease patients with dyskinesias. Brain. 2004;127:1075–1084.
   PubMed Web of Science ®Google Scholar
• Mishina M, Ishiwata K. Adenosine receptor PET imaging in human brain. Int Rev Neurobiol. 2014;119:51–69.
   PubMed Web of Science ®Google Scholar
• Correa M, Wisniecki A, Betz A, et al. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res. 2004;148:47–54.
   PubMed Web of Science ®Google Scholar
• Shiozaki S, Ichikawa S, Nakamura J, et al. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacol (Berl). 1999;147:90–95.
   PubMed Web of Science ®Google Scholar
• Hauber W, Neuscheler P, Nagel J, et al. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2A receptors in the caudate-putamen of rats. Eur J Neurosci. 2001;14:1287–1293.
   PubMed Web of Science ®Google Scholar
• Salamone JD. Preladenant, a novel adenosine A2A receptor antagonist for the potential treatment of parkinsonism and other disorders. Drugs. 2010;13:723–731.
   PubMed Web of Science ®Google Scholar
• Collins LE, Sager TN, Sams AG, et al. The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacol Biochem Behavior. 2012;100:498–505.
   PubMed Web of Science ®Google Scholar
• Kanda T, Shiozaki S, Shimada J, et al. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol. 1994;256:263–268.
   PubMed Web of Science ®Google Scholar
• Rose S, Ramsay Croft N, Jenner P. The novel adenosine A2A antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res. 2007;1133:110–114.
   PubMed Web of Science ®Google Scholar
• Koga K, Kurokawa M, Ochi M, et al. Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol. 2000;408:249–255.
   PubMed Web of Science ®Google Scholar
• Fenu S, Pinna A, Ongini E, et al. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol. 1997;321:143–147.
   PubMed Web of Science ®Google Scholar
• Ferré S, Rubio A, Fuxe K. Stimulation of adenosine A2 receptors induces catalepsy. Neurosci Lett. 1991;130:162–164.
   PubMed Web of Science ®Google Scholar
• Rose S, Jackson MJ, Smith LA, et al. The novel adenosine A2A receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Eur J Pharmacol. 2006;546:82–87.
   PubMed Web of Science ®Google Scholar
• Grondin R, Bedard PJ, Hadj Tahar A, et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology. 1999;52:1673–1677.
   PubMed Web of Science ®Google Scholar
• Hodgson RA, Bedard PJ, Varty GB, et al. Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders. Exp Neurol. 2010;225:384–390.
   PubMed Web of Science ®Google Scholar
• Kanda T, Tashiro T, Kuwana Y, et al. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport. 1998;9:2857–2860.
   PubMed Web of Science ®Google Scholar
• Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998;43:507–513.
   PubMed Web of Science ®Google Scholar
• Uchida S, Tashiro T, Kawai-Uchida M, et al. Adenosine A2A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets. J Pharmacol Sci. 2014;124:480–485.
   PubMed Web of Science ®Google Scholar
• Uchida S, Soshiroda K, Okita E, et al. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. Eur J Pharmacol. 2015;766:25–30.
   PubMed Web of Science ®Google Scholar
• Jones N, Bleickardt C, Mullins D, et al. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. Brain Res Bull. 2013;98:163–169.
   PubMed Web of Science ®Google Scholar
• Tronci E, Simola N, Borsini F, et al. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol. 2007;566:94–102.
   PubMed Web of Science ®Google Scholar
• Lundblad M, Vaudano E, Cenci MA. Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem. 2003;84:1398–1410.
   PubMed Web of Science ®Google Scholar
• Bibbiani F, Oh JD, Petzer JP, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol. 2003;184:285–294.
   PubMed Web of Science ®Google Scholar
• Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease. Expert Opin Invest Drugs. 2005;14:729–738.
   PubMed Web of Science ®Google Scholar
• Dungo R, Deeks ED. Istradefylline: first global approval. Drugs. 2013;73:875–882.
   PubMed Web of Science ®Google Scholar
• Saki M, Yamada K, Koshimura E, et al. In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:963–972.
   PubMed Web of Science ®Google Scholar
• Bekar L, Libionka W, Tian GF, et al. Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor. Nat Med. 2008;14:75–80.
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Brit J Pharmacol. 2006;147(Suppl 1):S252–S257.
   PubMed Web of Science ®Google Scholar
• Knebel W, Rao N, Uchimura T, et al. Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with parkinson’s disease. J Clin Pharmacol. 2011;51:40–52.
   PubMed Web of Science ®Google Scholar
• Müller T. Suitability of the adenosine antagonist istradefylline for the treatment of parkinson’s disease: pharmacokinetic and clinical considerations. Expert Opin Drug Metab Toxicol. 2013;9:1015–1024.
   PubMed Web of Science ®Google Scholar
• NOURIANZ™ (istradefylline) tablets, for oral use. US Prescribing information. Available at https://www.nourianz.com/assets/pdf/nourianz-full-prescribing-information.pdf. Last accessed February 1, 2021.
   Google Scholar
• Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology. 2003;61:297–303. .
   PubMed Web of Science ®Google Scholar
• Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A2A receptor antagonist treatment of parkinson’s disease. Neurology. 2003;61:293–296.
   PubMed Web of Science ®Google Scholar
• Poewe W. The role of COMT inhibition in the treatment of parkinson’s disease. Neurology. 2004;62:S31–8.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with parkinson’s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23:75–81.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Greeley DR, Zweig RM, et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord. 2010;16:16–20.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63:295–302.
   PubMed Web of Science ®Google Scholar
• Stacy M, Silver D, Mendis T, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70(23):2233–2240. .
   PubMed Web of Science ®Google Scholar
• Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with parkinson’s disease on levodopa with motor fluctuations. Mov Disord. 2008;23:2177–2185.
   PubMed Web of Science ®Google Scholar
• Pourcher E, Fernandez HH, Stacy M, et al. Istradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Related Disord. 2012;18(2):178–184. .
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kirin UK L. A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson’s Disease in Patients With Motor Response Complications on Levodopa Therapy. 2005. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00199394. Last accessed February 1, 2021.
   Google Scholar
• Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in parkinson’s disease: a randomized, controlled study. Mov Disord. 2010;25:1437–1443.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Kondo T. Japanese istradefylline study g. adenosine A2A receptor antagonist istradefylline reduces daily OFF time in parkinson’s disease. Mov Disord. 2013;28:1138–1141.
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kirin Pharma I. A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson’s Disease 2016. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01968031. Last accessed February 1, 2021.
   Google Scholar
• Kondo T, Mizuno Y. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol. 2015;38:41–46.
   PubMed Web of Science ®Google Scholar
• Factor S, Mark MH, Watts R, et al. A long-term study of istradefylline in subjects with fluctuating parkinson’s disease. Parkinsonism Related Disord. 2010;16:423–426.
   PubMed Web of Science ®Google Scholar
• Center for drug evaluation and research. Clinical Review: NDA 022075. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000MedR.pdf. Last accessed November 2020. Last accessed February 1, 2021.
   Google Scholar
• Takahashi M, Fujita M, Asai N, et al. Safety and effectiveness of istradefylline in patients with parkinson’s disease: interim analysis of a post-marketing surveillance study in japan. Expert Opin Pharmacother. 2018;19:1635–1642.
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kirin Co. L. Kyowa Hakko Kirin Initiates a Global Phase 3 Trial of Istradefylline (KW-6002) for Parkinson’s Disease 2013. Available from: https://www.kyowakirin.com/media_center/news_releases/2013/e20131121_01.html. Last accessed February 1, 2021.
   Google Scholar
• Kyowa Hakko Kirin Announces Top-Line Results of Global Phase 3 Trial of KW-6002 (Istradefylline) for Parkinson’s Disease [Internet]. 2016; December 13. Available from: https://www.kyowakirin.com/media_center/news_releases/2016/pdf/e20161213_01.pdf. Last accessed Jan 2021.
   Google Scholar
• Lewitt P, Aradi S, Hauser RA, et al. The challenge of developing adenosine A2 A antagonists for Parkinson disease: istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord. 2020;80(Supp 1):S54–S63.
   PubMedGoogle Scholar
• Hauser RA, Stocchi F, Rascol O, et al. Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol. 2015;72:1491–1500.
   PubMed Web of Science ®Google Scholar
• Center for drug evaluation and research. Summary Review: 022075Orig1s000. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000SumR.pdf. Last accessed February 1, 2021.
   Google Scholar
• Kyowa Kirin Announces FDA Approval of NOURIANZ™ (istradefylline) for Use in Parkinson’s Disease [Internet]. 2019; August 28. Available from: https://www.kyowakirin.com/media_center/news_releases/2019/e20190828_01.html. Last accessed Jan 2021.
   Google Scholar
• Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency. Available at https://www.kyowakirin.com/media_center/news_releases/2020/e20200106_01.html. Last accessed February 1, 2021.
   Google Scholar
• Jenner P, Mori A, Kanda T. Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson’s disease? Parkinsonism Relat Disord. 2020;80(Supp 1):S28–S36.
   PubMedGoogle Scholar
• Abe K, Fujita M, Yoshikawa H. Effectiveness of istradefylline for fatigue and quality of life in parkinson’s disease patients’ and of their caregivers’. Adv Parkinsons Dis. 2016;5:24–28.
   Google Scholar
• Nagayama H, Kano O, Murakami H, et al. Effect of istradefylline on mood disorders in Parkinson’s disease. J Neurol Sci. 2019;396:78–83.
   PubMed Web of Science ®Google Scholar
• Ito H, Fukutake S, Kamei T, et al. Clinical efficacy of istradefylline for depression in parkinson’s disease. J Neurol Neurosci. 2018;9:261.
   Google Scholar
• Kitta T, Yabe I, Kanno Y, et al. Long-term outcome of adenosine A2a receptor antagonist on lower urinary tract symptoms in male Parkinson disease patients. Clin Neuropharmacol. 2018;41:98–102.
   PubMed Web of Science ®Google Scholar
• Kitta T, Yabe I, Takahashi I, et al. Clinical efficacy of istradefylline on lower urinary tract symptoms in parkinson’s disease. Int J Urol. 2016;23:893–894.
   PubMed Web of Science ®Google Scholar
• Matsuura K, Kajikawa H, Tabei KI, et al. The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with parkinson’s disease. Neurosci Lett. 2018;662:158–161.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Miyamoto M, Miyamoto T, et al. Istradefylline improves daytime sleepiness in patients with parkinson’s disease: an open-label, 3-month study. J Neurol Sci. 2017;380:230–233.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Miyamoto T, Miyamoto M, et al. Could istradefylline be a treatment option for postural abnormalities in mid-stage parkinson’s disease? J Neurol Sci. 2018;385:131–133.
   PubMed Web of Science ®Google Scholar
• Iijima M, Orimo S, Terashi H, et al. Efficacy of istradefylline for gait disorders with freezing of gait in parkinson’s disease: a single-arm, open-label, prospective, multicenter study. Exp Opin Pharmacother. 2019;20:1405–1411.
   PubMed Web of Science ®Google Scholar
• Fujioka S, Yoshida R, Nose K, et al. A new therapeutic strategy with istradefylline for postural deformities in parkinson’s disease. Neurol Neurochir Pol. 2019;53:291–295.
   PubMed Web of Science ®Google Scholar
• Kataoka H, Sugie K. Does istradefylline really have a dystonic mechanism? J Neurol Sci. 2018;388:233–234.
   PubMed Web of Science ®Google Scholar
• Huang ZL, Zhang Z, Qu WM. Roles of adenosine and its receptors in sleep-wake regulation. Int Rev Neurobiol. 2014;119:349–371.
   PubMed Web of Science ®Google Scholar
• French IT, Muthusamy KA. A review of the pedunculopontine nucleus in parkinson’s disease. Front Aging Neurosci. 2018;10:99.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of parkinson’s disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep. 2005;5:275–283.
   PubMedGoogle Scholar
• Mitchell SL, Harper DW, Lau A, et al. Patterns of outcome measurement in parkinson’s disease clinical trials. Neuroepidemiology. 2000;19:100–108.
   PubMed Web of Science ®Google Scholar
• Kyowa Kirin Announces Positive Phase 2b Results for KW-6356 in Patients with Parkinson’s Disease [Internet]. 2020. Available from: https://www.kyowakirin.com/media_center/news_releases/2020/pdf/e20201021_01.pdf. Last accessed February 1, 2021.
   Google Scholar
• Hong CT, Chan L, Bai C-H. The effect of caffeine on the risk and progression of parkinson’s disease: a meta-analysis. Nutrients. 2020;12:1860.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kurokawa M, Aoyama S, et al. Neuroprotection by adenosine A2A receptor blockade in experimental models of parkinson’s disease. J Neurochem. 2002;80:262–270.
   PubMed Web of Science ®Google Scholar
• Cunha RA. Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinergic Sig. 2005;1:111–134.
   PubMedGoogle Scholar
• Kachroo A, Schwarzschild MA. Adenosine A2A receptor gene disruption protects in an alpha-synuclein model of parkinson’s disease. Ann Neurol. 2012;71:278–282.
   PubMed Web of Science ®Google Scholar
• Hu QD, Ren XP, Liu Y, et al. Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy. Exp Neurol. 2016;283:213–223.
   PubMed Web of Science ®Google Scholar
• Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in parkinson’s disease? Parkinsonism Relat Disord. 2020;80(Supp 1):S45–S53.
   PubMedGoogle Scholar
• Dai SS, Zhou YG, Li W, et al. Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injury. J Neurosci. 2010;30:5802–5810.
   PubMed Web of Science ®Google Scholar
• Brambilla R, Cottini L, Fumagalli M, et al. Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia. 2003;43:190–194.
   PubMed Web of Science ®Google Scholar
• Boison D, Chen JF, Fredholm BB. Adenosine signaling and function in glial cells. Cell Death Diff. 2010;17:1071–1082.
   PubMed Web of Science ®Google Scholar
• Hui CW, Zhang Y, Herrup K. Non-neuronal cells are required to mediate the effects of neuroinflammation: results from a neuron-enriched culture system. PLoS One. 2016;11:e0147134.
   PubMed Web of Science ®Google Scholar
• Webb JL, Ravikumar B, Atkins J, et al. Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278:25009–25013.
   PubMed Web of Science ®Google Scholar
• Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292–1295.
   PubMed Web of Science ®Google Scholar
• Sinha RA, Farah BL, Singh BK, et al. Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology. 2014;59:1366–1380.
   PubMed Web of Science ®Google Scholar
• Liu YW, Yang T, Zhao L, et al. Activation of Adenosine 2A receptor inhibits neutrophil apoptosis in an autophagy-dependent manner in mice with systemic inflammatory response syndrome. Sci Rep. 2016;6:33614.
   PubMed Web of Science ®Google Scholar
• Ferreira DG, Batalha VL, Vicente Miranda H, et al. Adenosine A2A receptors modulate alpha-synuclein aggregation and toxicity. Cereb Cortex. 2017;27:718–730.
   PubMed Web of Science ®Google Scholar
• Orr AG, Hsiao EC, Wang MM, et al. Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. Nat Neurosci. 2015;18:423–434.
   PubMed Web of Science ®Google Scholar
• Orr AG, Lo I, Schumacher H, et al. Istradefylline reduces memory deficits in aging mice with amyloid pathology. Neurobiol Dis. 2018;110:29–36.
   PubMed Web of Science ®Google Scholar
• Pierri M, Vaudano E, Sager T, et al. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology. 2005;48:517–524.
   PubMed Web of Science ®Google Scholar
• Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of parkinson’s disease. J Neurosci. 2001;21:Rc143.
   PubMed Web of Science ®Google Scholar